WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
WALTHAM, Mass., April 27, 2017 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2017 on Thursday, May 4, 2017. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 2971783. A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
